Valuing Biodiversity for Use in Pharmaceutical Research

"Biodiversity prospecting" has been touted as a mechanism for both discovering new pharmaceutical products and saving endangered ecosystems. It is unclear what values may arise from such activities, however. Evidence from transactions is incomplete and existing theoretical models are flawe...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of political economy Vol. 104; no. 1; pp. 163 - 185
Main Authors Simpson, R. David, Sedjo, Roger A., Reid, John W.
Format Journal Article
LanguageEnglish
Published Chicago The University of Chicago Press 01.02.1996
University of Chicago Press
University of Chicago, acting through its Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:"Biodiversity prospecting" has been touted as a mechanism for both discovering new pharmaceutical products and saving endangered ecosystems. It is unclear what values may arise from such activities, however. Evidence from transactions is incomplete and existing theoretical models are flawed. We calculate an upper bound on the value of the "marginal species." Even under favorable assumptions this bound is modest. Slightly modified assumptions lead to drastically lower estimates. We extend our findings to the value of the marginal hectare of habitat and find that the incentives for habitat conservation generated by private pharmaceutical research are also, at best, very modest.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-3808
1537-534X
DOI:10.1086/262021